Vimarsana
Biggest News Aggregation in the World

Page 5 - Compugen Ltd News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Compugen Ltd. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Compugen Ltd Today - Breaking & Trending Today

Compugen to Host Conference Call to Discuss Exclusive License Agreement with Gilead for COM503, Novel Immuno-Oncology Pre-Clinical Program Harnessing IL-18 Biology - Vimarsana News

Compugen to Host Conference Call to Discuss Exclusive License Agreement with Gilead for COM503, Novel Immuno-Oncology Pre-Clinical Program Harnessing IL-18 Biology

Conference call today, December 19, 2023, 8:30 AM ET to discuss the license agreementHOLON, Israel, Dec. 19, 2023 /PRNewswire/ -- Compugen Ltd. a clinical-stage cancer immunotherapy company and a...

Compugen Will Be Eligible to Receive $10 Million Milestone Payment Upon Dosing of First Patient in Astrazeneca Phase 3 Rilvegostomig Trial in Biliary Tract Cancer - Vimarsana News

Compugen Will Be Eligible to Receive $10 Million Milestone Payment Upon Dosing of First Patient in Astrazeneca Phase 3 Rilvegostomig Trial in Biliary Tract Cancer

Compugen Ltd. announced it will be eligible to receive a milestone payment of $10 million from AstraZeneca when the first patient is dosed in AstraZeneca's ARTEMIDE-Bil01 trial with rilvegostomig....

Related Topics:
Compugen Ltd
Compugen will be Eligible to Receive $10 Million Milestone Payment upon Dosing of First Patient in AstraZeneca Phase 3 Rilvegostomig Trial in Biliary Tract Cancer - Vimarsana News

Compugen will be Eligible to Receive $10 Million Milestone Payment upon Dosing of First Patient in AstraZeneca Phase 3 Rilvegostomig Trial in Biliary Tract Cancer

Dosing of first patient in Phase 3 trial of rilvegostomig, a PD-1/TIGIT bispecific antibody, will trigger $10 million milestone payment from AstraZenecaHOLON, Israel, Dec. 19, 2023 /PRNewswire/ --...

Compugen : 6K-License Agreement with Gilead and entitlement to receive a milestone payment of $10 million from AstraZeneca -December 19, 2023 at 07:24 am EST - Vimarsana News

Compugen : 6K-License Agreement with Gilead and entitlement to receive a milestone payment of $10 million from AstraZeneca -December 19, 2023 at 07:24 am EST

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF...

Why Is Cancer Immunotherapy-Focused Compugen Stock Is Trading Higher Today? - Vimarsana News

Why Is Cancer Immunotherapy-Focused Compugen Stock Is Trading Higher Today?

Gilead Sciences Inc GILD announced an agreement with Compugen Ltd CGEN to license its pre-clinical antibody program against IL-18 binding protein exclusively,…

Source: biztoc.com